PATENT CLAIM ANALYSIS

Application Number: 15980057
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "130100"]

Abstract:
This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

Claim (Index 3):
The method of  claim 1 , further comprising conjugating the antibody to an anti-cancer therapeutic agent.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 93.0
- Lexical Diversity: 2.23188
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14040024', '15816635', '13293608', '15613928', '12389503']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8268543014425523
- 35 USC 102 Novelty (BERT): 0.6461218178220536
- Combined Prediction Score: 0.8087810530805025
- Mean Citation Score: 697.32144
- Max Citation Score: 715.3533
- Similarity Product: 561.9682966513037

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test